Minn. Stat. § 62Q.1841
This is the official text of Minn. Stat. § 62Q.1841, part of Minnesota’s Stat — part of the compiled statutory law of Minnesota, published by the state as "Stat." Browse the sections below, each linked to its official government source.
Not legal advice. This page reproduces the official text of a government statute for reference only. Laws change, and how a statute applies depends on your specific facts. For advice about your situation, consult a licensed attorney in your state.
§ 62Q.1841 PROHIBITION ON USE OF STEP THERAPY FOR METASTATIC CANCER.
Official statutory text
§ Subdivision 1. Definitions. (a) For purposes of this section, the following definitions apply. (b) "Health plan" has the meaning given in section 62Q.01, subdivision 3 . Health plan includes health coverage provided by a county-based purchasing plan participating in a public program under chapter 256B or 256L or an integrated health partnership under section 256B.0755 . (c) "Stage four advanced metastatic cancer" means cancer that has spread from the primary or original site of the cancer to nearby tissues, lymph nodes, or other parts of the body. (d) "Step therapy protocol" has the meaning given in section 62Q.184, subdivision 1 .
§ Subd. 2. Prohibition on use of step therapy protocols. A health plan that provides coverage for the treatment of stage four advanced metastatic cancer or associated conditions must not limit or exclude coverage for a drug approved by the United States Food and Drug Administration that is on the health plan's prescription drug formulary by mandating that an enrollee with stage four advanced metastatic cancer or associated conditions follow a step therapy protocol if the use of the approved drug is consistent with: (1) a United States Food and Drug Administration-approved indication; and (2) a clinical practice guideline published by the National Comprehensive Care Network.
§ Subd. 2. Prohibition on use of step therapy protocols. A health plan that provides coverage for the treatment of stage four advanced metastatic cancer or associated conditions must not limit or exclude coverage for a drug approved by the United States Food and Drug Administration that is on the health plan's prescription drug formulary by mandating that an enrollee with stage four advanced metastatic cancer or associated conditions follow a step therapy protocol if the use of the approved drug is consistent with: (1) a United States Food and Drug Administration-approved indication; and (2) a clinical practice guideline published by the National Comprehensive Care Network.
Status: in_force · Read it on the official government site
Need a lawyer in Minnesota?
Find a Minnesota lawyer
About this page: Statute text is reproduced from official government publishers via the
Open US Law dataset
(Vaquill AI, snapshot v2026.08, CC BY 4.0). Primary legislative text like this is public domain under the government-edicts doctrine
(Georgia v. Public.Resource.Org, 2020). We link every section back to its official source so you can verify it independently.